SMAX
Semax
A synthetic heptapeptide: residues 4 to 7 of adrenocorticotropic hormone, Met-Glu-His-Phe, extended at the C-terminus with Pro-Gly-Pro. The added tripeptide is what resists enzymatic cleavage. The ACTH fragment it is built on has no corticotropic activity, and no receptor target for semax itself has been established in the published literature.
No registered human study names Semax as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains Semax. 53 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Semax; the registry search is fuzzy, so every match is re-checked. None of this says whether Semax works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
53
Readership
14,065
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of Semax in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Semax is, and what it has been studied for
Semax is tracked here. Its FDA substance identifier is I5FAL2585H.
No registered trial names Semax as an intervention, so there is no condition it has been formally studied in. It does have a literature: 53 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying Semax?
Papers published each year that name Semax in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 9 | 0 | Yes |
| 2018 | 4 | 0 | Yes |
| 2019 | 3 | 0 | Yes |
| 2020 | 7 | 0 | Yes |
| 2021 | 9 | 0 | Yes |
| 2022 | 4 | 0 | Yes |
| 2023 | 3 | 0 | Yes |
| 2024 | 4 | 0 | Yes |
| 2025 | 8 | 0 | Yes |
| 2026 | 5 | 0 | No |
53 papers between 2017 and 2026. A paper counts when “Semax” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Semax
53 indexed papers name Semax in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Functional Connectomic Approach to Studying Selank and Semax Effects
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
- Pharmacological Aspects of Neuro-Immune Interactions
- Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
- The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
- Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia
Collected 2026-08-02from PubMed, phrase-matched on “Semax” in title and abstract. Run the same search.
About Semax
A synthetic heptapeptide: residues 4 to 7 of adrenocorticotropic hormone, Met-Glu-His-Phe, extended at the C-terminus with Pro-Gly-Pro. The added tripeptide is what resists enzymatic cleavage. The ACTH fragment it is built on has no corticotropic activity, and no receptor target for semax itself has been established in the published literature.
- Also known as
- ACTH (4-7) PGP
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.